Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)
Clinical trial NCT04385277 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04385277
- Sponsor
- Children's Oncology Group
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-12-31
- Primary completion
- 2023-06-30
- Enrollment
- 41
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.